We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Subcutaneous Adipose Tissue in Cases With Polycystic Ovarian Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01310569
First Posted: March 8, 2011
Last Update Posted: March 8, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Gulhane School of Medicine
March 7, 2011
March 8, 2011
March 8, 2011
January 2009
August 2010   (Final data collection date for primary outcome measure)
Relationship of Subcutaneous Adipose Tissue with HOMA-IR and Plasma Adiponectin Levels in Cases with Polycystic Ovarian Syndrome [ Time Frame: 2 year ]
PCOS patients (the experimental group) had higher mean SFT values in all parts, mid-upper arm circumference values, whole body and trunk fat free mass amounts (FFM) and HOMA-IR values, while a lower adiponectin level.
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Subcutaneous Adipose Tissue in Cases With Polycystic Ovarian Syndrome
Relationship of Subcutaneous Adipose Tissue With HOMA-IR and Plasma Adiponectin Levels in Cases With Polycystic Ovarian Syndrome
This study aimed to search whether whole body and subcutaneous adipose tissues increase in PCOS patients and whether these tissues are related to HOMA-IR and plasma adiponectin levels.
Fifty-two patients with PCOS and fifty-tree healthy controls who were matched for body mass index (BMI) and age (p=0.430, p=0.112, respectively) were enrolled in the study. Biceps, triceps, subscapular and suprailiac skinfold thicknesses (SFT) of all cases were measured via caliper device; mid-upper arm circumference (MUAC) via a tape; and body fat distributions via a bioelectrical impedance device. Insulin resistance was calculated via HOMA-IR while ELISA was used to measure plasma adiponectin.
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with PCOS witout any other metabolik diseases
Polycystic Ovary Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
August 2010
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All of the women with PCOS had normal thyroid-stimulating hormone and prolactin (PRL) levels.

Exclusion Criteria:

  • Subjects with possible ovarian tumors, congenital adrenal hyperplasia, BMI greater than 35 kg/m2, any chronic renal or liver disease, were excluded from the study.
Sexes Eligible for Study: Female
18 Years to 42 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Turkey
 
 
NCT01310569
27.04.2010/1491-764-10
No
Not Provided
Not Provided
Aydogan Aydogdu, Gulhane School of Medicine
Gulhane School of Medicine
Not Provided
Study Director: Aydogan Aydogdu, MD Gulhane School of Medicine
Gulhane School of Medicine
August 2010